Market Overview

According to fortune business insights, The global immunoassay market size was valued at USD 37.19 billion in 2025. The market is projected to grow from USD 39.48 billion in 2026 to USD 63.72 billion by 2034, exhibiting a CAGR of 6.17% during the forecast period. North America dominated the immunoassay market with a market share of approximately 36% in 2025.

The analysis shows that top companies are investing more in immunoassay technologies because of the rising demand for early and accurate disease diagnosis. For example, healthcare systems increasingly prioritize preventive screening and early intervention, boosting diagnostic testing volumes for infectious diseases, cancer, and cardiovascular disorders. This trend indicates a strong demand for high-throughput, reliable, and cost-effective diagnostic solutions worldwide.

Major Players Profiled in the Market Report:

• F. Hoffmann-La Roche Ltd (Basel, Switzerland)
• Siemens Healthcare Private Limited (Erlangen, Germany)
• bioMérieux SA (Marcy-l'Étoile, France)
• Ortho Clinical Diagnostics (Raritan, U.S.)
• Sysmex Corporation (Kobe, Japan)
• Merck KGaA (Darmstadt, Germany)
• Agilent Technologies, Inc. (California, U.S.)
• DiaSorin S.p.A (Saluggia, Italy)
• Beckman Coulter Inc. (California, U.S.)

Segments

High Recurring Demand to Drive Consumables Segment Expansion

Based on product, the market is divided into instruments and consumables. The consumables segment holds the largest market share, representing approximately 62% of the market, owing to the recurring need for reagents, assay kits, and calibrators for every test performed, which creates a stable and continuous revenue stream.

Superior Sensitivity and Automation to Propel Chemiluminescence Segment Growth

By technology, the market is categorized into chemiluminescence immunoassay, ELISA, fluoroimmunoassay, radioimmunoassay, and others. The chemiluminescence immunoassay segment is leading the market as it offers superior sensitivity, a wide dynamic range, and is well-suited for fully automated, high-throughput platforms, making it the preferred format for modern diagnostics.

High Prevalence of Heart Disease to Propel Cardiology Segment Growth

Based on application, the market is segmented into cardiology, oncology, autoimmune diseases, and infectious diseases. The cardiology segment holds the largest market share owing to the high global prevalence of cardiovascular disorders and the increasing reliance on advanced diagnostic biomarkers for early detection, risk assessment, and patient management.